# Kiora Pharmaceuticals Inc: Form 10-K for the period ended Dec 31, 2017

- Company: [Kiora Pharmaceuticals Inc](/companies/kprx.md) (CIK 1372514)
- Form: 10-K
- Filed: 2018-03-02
- Accepted by EDGAR: Mar 2, 2018, 16:18 ET
- Period: 2017-12-31
- Accession: 0001144204-18-012542
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1372514/000114420418012542/tv486567_10k.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1372514/000114420418012542/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2017-12-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Research and development | 12 months, 2017-01-01 to 2017-12-31 | $10.3m | us-gaap:ResearchAndDevelopmentExpense |
| Interest expense | 12 months, 2017-01-01 to 2017-12-31 | $1.2k | us-gaap:InterestExpense |
| Income tax | 12 months, 2017-01-01 to 2017-12-31 | −$1.3m | us-gaap:IncomeTaxExpenseBenefit |
| Operating cash flow | 12 months, 2017-01-01 to 2017-12-31 | −$6.5m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months, 2017-01-01 to 2017-12-31 | $37.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2017-12-31 | $7.8m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2017-12-31 | $8.5m | us-gaap:AssetsCurrent |
| Total assets | at 2017-12-31 | $14.3m | us-gaap:Assets |
| Current liabilities | at 2017-12-31 | $14.8m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2017-12-31 | $16.2m | us-gaap:Liabilities |
| Shareholders' equity | at 2017-12-31 | −$1.9m | us-gaap:StockholdersEquity |

## Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. https://www.sec.gov/Archives/edgar/data/1372514/000114420418012542/tv486567_10k.htm

Filed Mar 2, 2018.
Source: SEC EDGAR, the filing index for accession 0001144204-18-012542. Last ingested by Listed: Nov 12, 2026, 17:43 ET. No prices; not investment advice.
